Literature DB >> 26385039

High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction.

Melissa A Daubert1, Joseph Massaro2, Lawrence Liao3, Ashish Pershad4, Suresh Mulukutla5, Erik Magnus Ohman3, Jeffrey Popma6, William W O'Neill7, Pamela S Douglas3.   

Abstract

BACKGROUND: Therapies that reverse pathologic left ventricular (LV) remodeling are often associated with improved outcomes. The incidence and impact of reverse LV remodeling after high-risk percutaneous coronary intervention (PCI) are unknown.
METHODS: The PROTECT II study was a multicenter trial in patients with complex, multivessel coronary artery disease and reduced ejection fraction (EF) that revealed an increase in visual EF after high-risk PCI. Among patients with quantitative echocardiography (LV volumes and biplane EF), we assessed the extent and predictors of reverse LV remodeling, defined as improved systolic function with an absolute increase in EF ≥5% and correlated these findings with clinical events.
RESULTS: Quantitative echocardiography was performed in 184 patients at baseline and longest follow-up. Mean EF at baseline was 27.1%. Ninety-three patients (51%) demonstrated reverse LV remodeling with an absolute increase in EF of 13.2% (P < .001). End-systolic volume decreased from 137.7 to 106.6 mL (P = .002). No significant change in EF or end-systolic volume was seen among non-remodelers. Reverse LV remodeling occurred more frequently in patients with more extensive revascularization (odds ratio, 7.52; 95% CI [1.31-43.25]) and was associated with significantly fewer major adverse events (composite of death/myocardial infarction/stroke/transient ischemic attack): 9.7% versus 24.2% (P = .009). There was also a greater reduction in New York Heart Association class III/IV heart failure among reverse LV remodelers (66.7% to 24.0%) than non-remodelers (56.3% to 34.4%), P = .045.
CONCLUSIONS: Reverse LV remodeling can occur after high-risk PCI in patients with complex coronary artery disease and reduced EF and is associated with improved clinical outcomes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26385039     DOI: 10.1016/j.ahj.2015.06.013

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

Review 1.  The Role for Cardiovascular Remodeling in Cardiovascular Outcomes.

Authors:  Nishant Krishna Sekaran; Anna Lisa Crowley; Fernanda Rodrigues de Souza; Elmiro Santos Resende; Sunil V Rao
Journal:  Curr Atheroscler Rep       Date:  2017-05       Impact factor: 5.113

2.  Predictive value of the echocardiographic noninvasive myocardial work index for left ventricular reverse remodeling in patients with multivessel coronary artery disease after percutaneous coronary intervention.

Authors:  Qiang Zheng; Lin Liu; Yuanyuan Liu; Cunying Cui; Yanan Li; Ying Wang; Yanbin Hu; Minfu Bai; Danqing Huang
Journal:  Quant Imaging Med Surg       Date:  2022-07

3.  Traditional Chinese medicine, Danlou tablets alleviate adverse left ventricular remodeling after myocardial infarction: results of a double-blind, randomized, placebo-controlled, pilot study.

Authors:  Shuai Mao; Lei Wang; Wenwei Ouyang; Yuanshen Zhou; Jianyong Qi; Liheng Guo; Minzhou Zhang; Aleksander Hinek
Journal:  BMC Complement Altern Med       Date:  2016-11-08       Impact factor: 3.659

4.  Transgenic overexpression of GTP cyclohydrolase 1 in cardiomyocytes ameliorates post-infarction cardiac remodeling.

Authors:  Yanan Liu; Shelley L Baumgardt; Juan Fang; Yang Shi; Shigang Qiao; Zeljko J Bosnjak; Jeannette Vásquez-Vivar; Zhengyuan Xia; David C Warltier; Judy R Kersten; Zhi-Dong Ge
Journal:  Sci Rep       Date:  2017-06-08       Impact factor: 4.379

5.  Evaluation of safety and efficacy of elective PCI in patients with cardiac insufficiency.

Authors:  Jiang-Xin Jing; Xiao-Lan Zhong; Sheng-Guo Chen
Journal:  Exp Ther Med       Date:  2016-12-27       Impact factor: 2.447

6.  Pericardial application as a new route for implanting stem-cell cardiospheres to treat myocardial infarction.

Authors:  Jianhua Zhang; Zheng Wu; Zepei Fan; Zixi Qin; Yingwei Wang; Jiayuan Chen; Maoxiong Wu; Yangxin Chen; Changhao Wu; Jingfeng Wang
Journal:  J Physiol       Date:  2018-05-07       Impact factor: 5.182

7.  Initial Invasive or Conservative Strategy in Heart Failure With Preserved Ejection Fraction and Coronary Artery Disease.

Authors:  Jun Gu; Jian-An Pan; Jun-Feng Zhang; Chang-Qian Wang
Journal:  Front Cardiovasc Med       Date:  2022-03-18

8.  Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.

Authors:  Mohammad Abumayyaleh; Jonathan Demmer; Carina Krack; Christina Pilsinger; Ibrahim El-Battrawy; Michael Behnes; Assem Aweimer; Andreas Mügge; Siegfried Lang; Ibrahim Akin
Journal:  Am J Cardiovasc Drugs       Date:  2022-03-30       Impact factor: 3.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.